Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib and Acalabrutinib in Relapsed or Refractory High-risk CLL
NCT03328273Phase 1Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ceralasertib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Jan 2018; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03328273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328273.